MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Advanced Breast Cancer Therapies
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

898 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
898 works in the cohort · of 4,299,418page 1 of 18

Labels cover 3 of 898 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 898 of 898 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn, Miguel Martín, Hope S. Rugo, Stephen E. Jones, Seock‐Ah Im, Karen A. Gelmon +9 more
2016· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · noneconsensus · none
2,948
citations
affno abstractunlabeled
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko, Jungsil Ro, Seock‐Ah Im, Norikazu Masuda +12 more
2016· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
1,822
citations
affunlabeled
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy +25 more
2024· article· en· New England Journal of Medicine· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
357
citations
affno abstractunlabeled
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney, Andrew Wardley, Stefania Zambelli, John Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci +11 more
2020· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
261
citations
affgemma · no categorygpt · no categorymodels agree
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, Angela DeMichele, Sherene Loi, Jungsil Ro +8 more
2016· article· en· The Oncologist· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
246
citations
next →

How this was built: Screen · Findings · About